Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

被引:269
作者
Garg A. [1 ]
Balthasar J.P. [1 ]
机构
[1] Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, Buffalo
基金
美国国家卫生研究院;
关键词
Antibody; FcRn; IgG; Neonatal Fc receptor; PBPK; Pharmacokinetics;
D O I
10.1007/s10928-007-9065-1
中图分类号
学科分类号
摘要
Although it is known that FcRn, the neonatal Fc-receptor, functions to protect immune gamma globulin (IgG) from elimination, the influence of FcRn on the tissue distribution of IgG has not been quantified. In the present work, a physiologically-based pharmacokinetic (PBPK) model has been developed to characterize and predict IgG disposition in plasma and in tissues. The model includes nine major compartments, connected in an anatomical manner, to represent tissues known to play a significant role in IgG disposition. Each tissue compartment was subdivided into vascular, endosomal and interstitial spaces. IgG transport between the blood and interstitial compartments may proceed by convection through paracellular pores in the vascular endothelium, or via FcRn-mediated transcytosis across vascular endosomal cells. The model was utilized to characterize plasma concentration-time data for 7E3, a monoclonal antiplatelet IgG1 antibody, in control and FcRn-knockout (KO) mice. These data showed that high dose intravenous immunoglobulin (IVIG), 1g/kg, increased 7E3 clearance in control mice from 5.2 ± 0.3 to 14.4 ± 1.4 ml/d/kg; however, IVIG failed to increase the clearance of 7E3 in KO mice (72.5 ± 4.0 vs. 61.0 ± 3.6 ml/d/kg). Based on model fitting to the 7E3 plasma concentration data, simulations were conducted to predict tissue concentrations of IgG in control and in KO mice, and the predictions were then tested by assessing 7E3 tissue distribution in KO mice and control mice. 7E3 was radiolabeled with Iodine-125 using chloramine T method, and 125I-7E3 IgG was administered at a dose of 8 mg/kg to control and KO mice. At various time points, sub-groups of 3 mice were sacrificed, blood and tissue samples were collected, and radioactivity assessed by gamma counting. PBPK model performance was assessed by comparing model predictions with the observed data. The model accurately predicted 7E3 tissue concentrations, with mean predicted vs. observed AUC ratios of 1.04 ± 0.2 and 0.86 ± 0.3 in control and FcRn-KO mice. The PBPK model, which incorporates the influence of FcRn on IgG clearance and disposition, was found to provide accurate predictions of IgG tissue kinetics in control and FcRn-knockout mice. © 2007 Springer Science+Business Media, LLC.
引用
收藏
页码:687 / 709
页数:22
相关论文
共 61 条
[11]  
Junghans R.P., Anderson C.L., The protection receptor for IgG catabolism is the beta2-microglobulin- containing neonatal intestinal transport receptor, Proc Natl Acad Sci USA, 93, pp. 5512-5516, (1996)
[12]  
Dall Acqua W.F., Woods R.M., Ward E.S., Palaszynski S.R., Patel N.K., Brewah Y.A., Wu H., Kiener P.A., Langermann S., Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences, J Immunol, 169, pp. 5171-5180, (2002)
[13]  
Ghetie V., Popov S., Borvak J., Radu C., Matesoi D., Medesan C., Ober R.J., Ward E.S., Increasing the serum persistence of an IgG fragment by random mutagenesis, Nat Biotechnol, 15, pp. 637-640, (1997)
[14]  
Borvak J., Richardson J., Medesan C., Antohe F., Radu C., Simionescu M., Ghetie V., Ward E.S., Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice, Int Immunol, 10, pp. 1289-1298, (1998)
[15]  
Ghetie V., Ward E.S., FcRn: The MHC class I-related receptor that is more than an IgG transporter, Immunol Today, 18, pp. 592-598, (1997)
[16]  
Israel E.J., Taylor S., Wu Z., Mizoguchi E., Blumberg R.S., Bhan A., Simister N.E., Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells, Immunology, 92, pp. 69-74, (1997)
[17]  
Baxter L.T., Zhu H., MacKensen D.G., Jain R.K., Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice, Cancer Res, 54, pp. 1517-1528, (1994)
[18]  
Dickinson B.L., Badizadegan K., Wu Z., Ahouse J.C., Zhu X., Simister N.E., Blumberg R.S., Lencer W.I., Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line, J Clin Invest, 104, pp. 903-911, (1999)
[19]  
Lobo E.D., Hansen R.J., Balthasar J.P., Antibody pharmacokinetics and pharmacodynamics, J Pharm Sci, 93, pp. 2645-2668, (2004)
[20]  
Tang L., Persky A.M., Hochhaus G., Meibohm B., Pharmacokinetic aspects of biotechnology products, J Pharm Sci, 93, pp. 2184-2204, (2004)